TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00832637
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
Study: NCT03681197
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
Study: NCT03681197
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
Study: NCT01155375
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Experimental: Ferumoxytol
Study: NCT00511719
Drug: Technosphere Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48U
Study: NCT00511719
Drug: Actrapid
Normalized name: Pork Actrapid
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24IU
Study: NCT00357942
Drug: morphine solution for injection
Normalized name: morphine Injectable Solution
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
Study: NCT03245970
Drug: Labetalol Hydrocholoride 200 mg orally every 12 hours
Normalized name: labetalol hydrochloride 200 MG
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
Study: NCT03245970
Drug: Nifedipine 60 mg orally daily
Normalized name: nifedipine 60 MG
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
Study: NCT03245970
Drug: Atenolol 25 mg daily
Normalized name: atenolol 25 MG
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
Study: NCT00357942
Drug: morphine mouthwash
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
Study: NCT00219921
Drug: Intrathecal morphine at surgery, 0.1mg and placebo
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00219921
Drug: Patient Controlled Analgesia with iv morphine and placebo
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02901041
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
Study: NCT02901041
Drug: Placebo (for Zonisamide)
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sugar pills manufactured to mimic Zonisamide capsules.
Study: NCT02757196
Drug: Rituximab plus methylprednisolone
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab （1000mg IV day1, week 3, week 17 , and week 19）
Study: NCT02757196
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
Study: NCT00219921
Drug: intrathecal morphine AND patient controlled analgesia with iv morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03249714
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
Study: NCT03249714
Drug: Matching placebo of ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching placebo in pre-filled syringes
Study: NCT03425838
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
Study: NCT00887250
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
Study: NCT00887250
Drug: Comparator: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
Study: NCT00689104
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT00689104
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules
Study: NCT00689104
Drug: Placebo to Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching mirabegron placebo tablets.
Study: NCT00689104
Drug: Placebo to Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching tolterodine placebo capsules.
Study: NCT04467957
Drug: Initiation of CFTR Modulator
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled contrast for MRI occurring at each visit
Study: NCT04467957
Drug: Hyperpolarized Xenon 129
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled contrast for MRI occurring at each visit
Study: NCT03813108
Drug: Atovaquone / Proguanil Oral Tablet [Malarone]
Normalized name: atovaquone / proguanil Oral Tablet [Malarone]
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
Study: NCT01258374
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir, 400 mg bid
Study: NCT03399487
Drug: LDK378(Ceritinib)
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.
Study: NCT00852046
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
Study: NCT01440712
Drug: Gastrografin
Normalized name: Gastrografin
DrugBank: Diatrizoate (DB00271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 100 ml of gastrografin by the nasogastric tube, only once.
Study: NCT01440712
Drug: physiological serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
Study: NCT02479867
Drug: Cefadroxil
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet from test vs 1 tablet from reference
Study: NCT05547659
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group
Study: NCT00093808
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00315432
Drug: Pegylated Interferon and Ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00679653
Drug: sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-wks, sibutramine, 10 mg, capsules, once daily
Study: NCT00679653
Drug: sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-wks, sibutramine, 15 mg, capsules, once daily
Study: NCT00679653
Drug: verapamil/trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 wk Run-in phase, antihypertensive therapy only
Study: NCT00679653
Drug: metoprolol/HCT
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 wk Run-in phase, antihypertensive therapy only
Study: NCT00679653
Drug: felodipine/ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 wk Run-in phase, antihypertensive therapy only
Study: NCT00701220
Drug: Atorvastatin Calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
Study: NCT00214838
Drug: Atiprimod
Normalized name: Atiprimod
DrugBank: Atiprimod (DB05513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00427336
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 by vein daily over 30 minutes
Study: NCT01258374
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir, 800 mg QD + ritonavir 100 mg QD
Study: NCT01190670
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral and Intravenous
Study: NCT00427336
Drug: Antithymocyte Globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg/kg by vein daily over 4 hours
Study: NCT00336544
Drug: Cethromycin
Normalized name: Cethromycin
DrugBank: Cethromycin (DB06419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cethromycin 300 mg once per day (QD) for 7 days, administered orally
Study: NCT00994500
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03599596
Drug: Sulphadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
Study: NCT03599596
Drug: Sulphadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
Study: NCT04553419
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin capsule: TEVA Cephalexin Cephalexin suspension: LUPIN Cephalexin
Study: NCT00076570
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00076570
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00994500
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00816348
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
Study: NCT00465725
Drug: Picoplatin
Normalized name: Picoplatin
DrugBank: Picoplatin (DB04874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
Study: NCT00843349
Drug: Lanthanum Carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phosphorus binder
Study: NCT00544219
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/day p.o. per cycle
Study: NCT00544219
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
Study: NCT02926937
Drug: Sotagliflozin (SAR439954)
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet;~Route of administration: oral
Study: NCT00454389
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
Study: NCT02215538
Drug: OROS methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02425709
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive oral tramadol 50 mg 1 hour before the procedure
Study: NCT03513874
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
Study: NCT01719133
Drug: Histamine
Normalized name: Histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: positive control
Study: NCT03513874
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will continue insulin therapy following physicians' instructions.
Study: NCT01273090
Drug: imetelstat sodium
Normalized name: imetelstat sodium
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00984425
Drug: Lapatinib and Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different dosages of two drug
Study: NCT02229045
Drug: Albumin Bound Paclitaxel
Normalized name: Albumin bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
Study: NCT02229045
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
Study: NCT02207361
Drug: Paclitaxel, Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
Study: NCT02207361
Drug: Paclitaxel, Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
Study: NCT01601483
Drug: MC-1101
Normalized name: MC-3
DrugBank: MC-1 (DB05315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Ophthalmic Solution TID
Study: NCT01601483
Drug: MC-1101 Vehicle
Normalized name: MC-3
DrugBank: MC-1 (DB05315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution, TID
Study: NCT02723877
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: non.taxane microtubule dynamics inhibitor
Study: NCT00655863
Drug: Alogliptin and Pioglitazone
Normalized name: Alogliptin and Pioglitazone Tablets
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
Study: NCT00655863
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Study: NCT02014272
Drug: RIN 150
Normalized name: aspirin 150 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
Study: NCT00691275
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00691275
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01688713
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
Study: NCT04141163
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet
Study: NCT01781702
Drug: Pelubiprofen 30 mg
Normalized name: Flurbiprofen
DrugBank: Pelubiprofen (DB12150)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01781702
Drug: Celebrex 200 mg
Normalized name: Celebrex 200 MG Oral Capsule
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04400318
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: solution for injection subcutaneous
Study: NCT05541419
Drug: Budesonide Nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
Study: NCT00616161
Drug: Istaroxime
Normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microgram/kg/min IV for 6 hours
Study: NCT00616161
Drug: Istaroxime
Normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 microgram/kg/min IV for 6 hours
Study: NCT00616161
Drug: Istaroxime
Normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 microgram/kg/min IV for 6 hours
Study: NCT01085487
Drug: Levonorgestrel (Mirena, BAY86-5028)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women using Mirena for treatment of menorrhagia
Study: NCT01085487
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
Study: NCT01085487
Drug: Antifibrinolytic treatment
Normalized name: Hongo Killer Treatment
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrinolytic treatment (such as tranexamic acid)
Study: NCT00445692
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00445692
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given Orally (PO)
Study: NCT00872196
Drug: ABT-072
Normalized name: ABT-072
DrugBank: ABT-072 (DB15156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples are being taken from subjects previously treated with ABT-072.
Study: NCT03766594
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
Study: NCT02663258
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04688021
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg/m2/day administered IV day -10 through -9.